Key points are not available for this paper at this time.
Introduction The recent advent of personalised assays capable of detecting circulating cell-free tumour DNA (ctDNA) has enabled detection of molecular residual disease (MRD) and recurrence following curative-intent therapy. We conducted LIONESS, a single-centre prospective cohort study to assess ctDNA in patients with HNSCC receiving primary surgery with curative intent to determine whether post-operative ctDNA detection can act as a biomarker for surgical tumour clearance and to evaluate the potential of personalised ctDNA analysis for early molecular-level detection of relapse or prior to clinically confirmed recurrence.
Flach et al. (Fri,) studied this question.